The US Department of Health and Human Services is to cancel contracts and pull funding for some vaccines that are being developed to fight respiratory viruses like Covid-19 and the flu. Robert F ...

With a market cap of $10.7 billion, Moderna, Inc. (MRNA) is a biotechnology company specializing in the development of ...

The Department of Health and Human Services is going to cancel contracts and pull funding for these projects, Robert F ...

Kennedy announced in a statement Tuesday that 22 projects, totaling $500 million, to develop vaccines using mRNA technology ...

A new UK study shows that vaccinating pregnant women against RSV has led to a staggering 72% drop in hospitalizations of newborns with severe lung infections. By passing virus-fighting antibodies ...

Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond pulmonology, including poor kidney outcomes and cardiovascular conditions ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the importance of timely vaccination and nirsevimab administration.

Here's what RSV is, why it especially impacts the youngest and oldest members of society and how it is usually treated.

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older adults long-term protection against the infection, even if efficacy ...